Simplify Glycoanalysis with Recombinant Prokaryotic Lectins.
Glycosylation is a post-translational modification (PTM) that can influence protein structure and function. It is therefore a Critical Quality Attribute (CQA) for biotherapeutic manufacturing, where it must be closely monitored to assure product safety and efficacy.
Glycoanalysis is typically performed using HPLC and MS-based approaches that yield highly detailed information about a protein’s glycosylation profile. However, these methods are complex, time consuming, and expensive, and can often be limited in terms of throughput.
Recombinant prokaryotic lectins (RPLs) can be immobilised on a broad range of biosensors, including those used for performing Biolayer Interferometry (BLI). The Sartorius Octet BLI system overcomes limitations in throughput, performance, and cost associated with technologies such as HPLC and can be combined with RPL biosensors for rapid, label-free glycoanalysis in real time.
Lectins represent powerful tools for glycoanalysis since they recognise and bind distinct glycans. Recombinant prokaryotic lectins (RPLs) offer superior specificity, consistency, and scalability over commercially available plant-based lectins.
By using recombinant prokaryotic lectins (RPLs) within biomanufacturing you will notice:
